Biodexa Pharmaceuticals Plc BDRX
Biodexa Pharmaceuticals Plc (Nasdaq: BDRX) is an oncology drug developer. Its lead program, eRapa, is in Phase 3 for Familial adenomatous polyposis (FAP). Its next catalyst on record is eRapa (Serenta): Pre-specified futility analysis for eRapa Phase 3 trial in FAP could occur early next year. (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: eRapa (Serenta) — Pre-specified futility analysis for eRapa Phase 3 trial in FAP could occur early next year. (Q1 2027). 13 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| eRapa | Familial adenomatous polyposis (FAP) | small molecule | Phase 3 |
| eRapa | Non-muscle invasive bladder cancer (NMIBC) | small molecule | Phase 2 |
| MTX240 (OPB-171775) | GIST | small molecule | Pre-clinical |
Recent results and decisions
- Oct 14, 2026completed enrollment Biodexa enrolled 100 patients in its registrational Phase 3 trial of eRapa in FAP (Serenta trial).
Enrolment of the 100th patient represents an important milestone for Serenta and reflects the continued strong recruitment performance across our participating sites.
Filing - Oct 13, 2026completed enrollment Biodexa enrolled 100 patients in its registrational Phase 3 Serenta trial of eRapa in FAP.
Biodexa Pharmaceuticals PLC is pleased to announce that it has enrolled 100 patients in its registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis (FAP).
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.